{"id":"https://openalex.org/W4398237253","doi":"https://doi.org/10.1128/aac.00236-24","title":"Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection","display_name":"Patient outcomes by baseline pathogen resistance phenotype and genotype in CERTAIN-1, a Phase 3 study of cefepime-taniborbactam versus meropenem in adults with complicated urinary tract infection","publication_year":2024,"publication_date":"2024-05-23","ids":{"openalex":"https://openalex.org/W4398237253","doi":"https://doi.org/10.1128/aac.00236-24","pmid":"https://pubmed.ncbi.nlm.nih.gov/38780262","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/11232400"},"language":"en","primary_location":{"id":"doi:10.1128/aac.00236-24","doi":"https://doi.org/10.1128/aac.00236-24","is_oa":true,"landing_page_url":"https://doi.org/10.1128/aac.00236-24","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.1128/aac.00236-24","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5063290824","display_name":"Greg Moeck","orcid":"https://orcid.org/0000-0001-7827-7227","observed_orcids":["https://orcid.org/0000-0001-7827-7227"]},"institutions":[{"id":"https://openalex.org/I4210124987","display_name":"VenatoRx Pharmaceuticals (United States)","ror":"https://ror.org/02s3j1d69","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124987"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Greg Moeck","raw_affiliation_strings":["Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA"],"raw_orcid":"https://orcid.org/0000-0001-7827-7227","affiliations":[{"raw_affiliation_string":"Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA","institution_ids":["https://openalex.org/I4210124987"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5084081858","display_name":"Leanne B. Gasink","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Leanne B. Gasink","raw_affiliation_strings":["LBG Consulting, LLC, Saint Davids, Pennsylvania, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"LBG Consulting, LLC, Saint Davids, Pennsylvania, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5041157580","display_name":"Rodrigo Elisandro Mendes","orcid":"https://orcid.org/0000-0002-8648-1137","observed_orcids":["https://orcid.org/0000-0002-8648-1137"]},"institutions":[{"id":"https://openalex.org/I4210121169","display_name":"JMI Laboratories","ror":"https://ror.org/02qv6pw23","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210121169"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Rodrigo E. Mendes","raw_affiliation_strings":["JMI Laboratories, North Liberty, Iowa, USA"],"raw_orcid":"https://orcid.org/0000-0002-8648-1137","affiliations":[{"raw_affiliation_string":"JMI Laboratories, North Liberty, Iowa, USA","institution_ids":["https://openalex.org/I4210121169"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5011819313","display_name":"Leah N. Woosley","orcid":"https://orcid.org/0000-0002-1244-6830","observed_orcids":["https://orcid.org/0000-0002-1244-6830"]},"institutions":[{"id":"https://openalex.org/I4210121169","display_name":"JMI Laboratories","ror":"https://ror.org/02qv6pw23","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210121169"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Leah N. Woosley","raw_affiliation_strings":["JMI Laboratories, North Liberty, Iowa, USA"],"raw_orcid":"https://orcid.org/0000-0002-1244-6830","affiliations":[{"raw_affiliation_string":"JMI Laboratories, North Liberty, Iowa, USA","institution_ids":["https://openalex.org/I4210121169"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090154986","display_name":"MaryBeth Dorr","orcid":"https://orcid.org/0000-0002-0397-7146","observed_orcids":["https://orcid.org/0000-0002-0397-7146"]},"institutions":[{"id":"https://openalex.org/I4210124987","display_name":"VenatoRx Pharmaceuticals (United States)","ror":"https://ror.org/02s3j1d69","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124987"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"MaryBeth Dorr","raw_affiliation_strings":["Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA"],"raw_orcid":"https://orcid.org/0000-0002-0397-7146","affiliations":[{"raw_affiliation_string":"Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA","institution_ids":["https://openalex.org/I4210124987"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027867701","display_name":"Hongzi Chen","orcid":"https://orcid.org/0009-0002-1561-952X","observed_orcids":["https://orcid.org/0009-0002-1561-952X"]},"institutions":[{"id":"https://openalex.org/I4210124987","display_name":"VenatoRx Pharmaceuticals (United States)","ror":"https://ror.org/02s3j1d69","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124987"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hongzi Chen","raw_affiliation_strings":["Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA"],"raw_orcid":"https://orcid.org/0009-0002-1561-952X","affiliations":[{"raw_affiliation_string":"Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA","institution_ids":["https://openalex.org/I4210124987"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045750331","display_name":"Florian Wagenlehner","orcid":"https://orcid.org/0000-0002-2909-0797","observed_orcids":["https://orcid.org/0000-0002-2909-0797"]},"institutions":[{"id":"https://openalex.org/I200763008","display_name":"Justus-Liebig-Universit\u00e4t Gie\u00dfen","ror":"https://ror.org/033eqas34","country_code":"DE","type":"education","lineage":["https://openalex.org/I200763008"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Florian M. Wagenlehner","raw_affiliation_strings":["Justus Liebig University, Giessen, Germany"],"raw_orcid":"https://orcid.org/0000-0002-2909-0797","affiliations":[{"raw_affiliation_string":"Justus Liebig University, Giessen, Germany","institution_ids":["https://openalex.org/I200763008"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5090036345","display_name":"Tim Henkel","orcid":"https://orcid.org/0000-0001-6347-5247","observed_orcids":["https://orcid.org/0000-0001-6347-5247"]},"institutions":[{"id":"https://openalex.org/I4210124987","display_name":"VenatoRx Pharmaceuticals (United States)","ror":"https://ror.org/02s3j1d69","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124987"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Tim Henkel","raw_affiliation_strings":["Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA"],"raw_orcid":"https://orcid.org/0000-0001-6347-5247","affiliations":[{"raw_affiliation_string":"Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA","institution_ids":["https://openalex.org/I4210124987"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5053622214","display_name":"Paul C. McGovern","orcid":"https://orcid.org/0000-0002-5906-2818","observed_orcids":["https://orcid.org/0000-0002-5906-2818"]},"institutions":[{"id":"https://openalex.org/I4210124987","display_name":"VenatoRx Pharmaceuticals (United States)","ror":"https://ror.org/02s3j1d69","country_code":"US","type":"company","lineage":["https://openalex.org/I4210124987"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Paul C. McGovern","raw_affiliation_strings":["Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA"],"raw_orcid":"https://orcid.org/0000-0002-5906-2818","affiliations":[{"raw_affiliation_string":"Venatorx Pharmaceuticals, Inc., Malvern, Pennsylvania, USA","institution_ids":["https://openalex.org/I4210124987"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5063290824"],"corresponding_institution_ids":["https://openalex.org/I4210124987"],"apc_list":null,"apc_paid":null,"fwci":10.7053,"has_fulltext":true,"cited_by_count":29,"citation_normalized_percentile":{"value":0.99007348,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":88,"max":100},"biblio":{"volume":"68","issue":"7","first_page":"e0023624","last_page":"e0023624"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11232","display_name":"Urinary Tract Infections Management","score":0.5932999849319458,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T11232","display_name":"Urinary Tract Infections Management","score":0.5932999849319458,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10147","display_name":"Antibiotic Resistance in Bacteria","score":0.3986999988555908,"subfield":{"id":"https://openalex.org/subfields/2726","display_name":"Microbiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11036","display_name":"Antibiotics Pharmacokinetics and Efficacy","score":0.003000000026077032,"subfield":{"id":"https://openalex.org/subfields/2736","display_name":"Pharmacology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/meropenem","display_name":"meropenem","score":0.9990000128746033},{"id":"https://openalex.org/keywords/complicated-urinary-tract-infection","display_name":"complicated urinary tract infection","score":0.9990000128746033},{"id":"https://openalex.org/keywords/acute-pyelonephritis","display_name":"acute pyelonephritis","score":0.9909999966621399},{"id":"https://openalex.org/keywords/carbapenem-resistance","display_name":"carbapenem resistance","score":0.7889999747276306},{"id":"https://openalex.org/keywords/extended-spectrum-beta-lactamase","display_name":"extended-spectrum beta-lactamase","score":0.925000011920929},{"id":"https://openalex.org/keywords/ampc-beta-lactamase","display_name":"AmpC beta-lactamase","score":0.9020000100135803},{"id":"https://openalex.org/keywords/beta-lactamase-genes","display_name":"beta-lactamase genes","score":0.8100000023841858},{"id":"https://openalex.org/keywords/enterobacterales","display_name":"Enterobacterales","score":0.8629999756813049},{"id":"https://openalex.org/keywords/pseudomonas-aeruginosa","display_name":"Pseudomonas aeruginosa","score":0.9980000257492065},{"id":"https://openalex.org/keywords/escherichia-coli","display_name":"Escherichia coli","score":0.9139999747276306},{"id":"https://openalex.org/keywords/oxa-48","display_name":"OXA-48","score":0.8169999718666077},{"id":"https://openalex.org/keywords/kpc-3","display_name":"KPC-3","score":0.8859999775886536},{"id":"https://openalex.org/keywords/ndm-1","display_name":"NDM-1","score":0.9959999918937683},{"id":"https://openalex.org/keywords/multidrug-resistance","display_name":"multidrug resistance","score":0.6269999742507935},{"id":"https://openalex.org/keywords/test-of-cure","display_name":"test of cure","score":0.6439999938011169}],"concepts":[{"id":"https://openalex.org/C2777050379","wikidata":"https://www.wikidata.org/wiki/Q2552927","display_name":"Cefepime","level":5,"score":0.987234354019165},{"id":"https://openalex.org/C2779375183","wikidata":"https://www.wikidata.org/wiki/Q421670","display_name":"Meropenem","level":4,"score":0.9187231063842773},{"id":"https://openalex.org/C2777637488","wikidata":"https://www.wikidata.org/wiki/Q31856","display_name":"Pseudomonas aeruginosa","level":3,"score":0.5981611609458923},{"id":"https://openalex.org/C2776685102","wikidata":"https://www.wikidata.org/wiki/Q410897","display_name":"Carbapenem","level":3,"score":0.5856777429580688},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.5297031402587891},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.455980122089386},{"id":"https://openalex.org/C547475151","wikidata":"https://www.wikidata.org/wiki/Q25419","display_name":"Escherichia coli","level":3,"score":0.4105414152145386},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.3862498998641968},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.35201773047447205},{"id":"https://openalex.org/C94665300","wikidata":"https://www.wikidata.org/wiki/Q63391344","display_name":"Antibiotic resistance","level":3,"score":0.24095317721366882},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.23435086011886597},{"id":"https://openalex.org/C2779631663","wikidata":"https://www.wikidata.org/wiki/Q425152","display_name":"Imipenem","level":4,"score":0.22270804643630981},{"id":"https://openalex.org/C523546767","wikidata":"https://www.wikidata.org/wiki/Q10876","display_name":"Bacteria","level":2,"score":0.12681695818901062},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.08542925119400024},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0429854691028595}],"mesh":[{"descriptor_ui":"D000077723","descriptor_name":"Cefepime","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000077723","descriptor_name":"Cefepime","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000077731","descriptor_name":"Meropenem","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000077731","descriptor_name":"Meropenem","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000900","descriptor_name":"Anti-Bacterial Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D001426","descriptor_name":"Bacterial Proteins","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D001618","descriptor_name":"beta-Lactamases","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":true},{"descriptor_ui":"D001889","descriptor_name":"Borinic Acids","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002264","descriptor_name":"Carboxylic Acids","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002511","descriptor_name":"Cephalosporins","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D002511","descriptor_name":"Cephalosporins","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004926","descriptor_name":"Escherichia coli","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D004926","descriptor_name":"Escherichia coli","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005838","descriptor_name":"Genotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008826","descriptor_name":"Microbial Sensitivity Tests","qualifier_ui":null,"qualifier_name":null,"is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010641","descriptor_name":"Phenotype","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011550","descriptor_name":"Pseudomonas aeruginosa","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D011550","descriptor_name":"Pseudomonas aeruginosa","qualifier_ui":"Q000235","qualifier_name":"genetics","is_major_topic":false},{"descriptor_ui":"D014552","descriptor_name":"Urinary Tract Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D014552","descriptor_name":"Urinary Tract Infections","qualifier_ui":"Q000382","qualifier_name":"microbiology","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1128/aac.00236-24","doi":"https://doi.org/10.1128/aac.00236-24","is_oa":true,"landing_page_url":"https://doi.org/10.1128/aac.00236-24","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:11232400","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/11232400","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11232400/pdf/aac.00236-24.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrob Agents Chemother","raw_type":"Text"},{"id":"pmid:38780262","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/38780262","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial agents and chemotherapy","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.1128/aac.00236-24","doi":"https://doi.org/10.1128/aac.00236-24","is_oa":true,"landing_page_url":"https://doi.org/10.1128/aac.00236-24","pdf_url":null,"source":{"id":"https://openalex.org/S47215897","display_name":"Antimicrobial Agents and Chemotherapy","issn_l":"0066-4804","issn":["0066-4804","1070-6283","1098-6596"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-b","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320263","host_organization_name":"American Society for Microbiology","host_organization_lineage":["https://openalex.org/P4310320263"],"host_organization_lineage_names":["American Society for Microbiology"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antimicrobial Agents and Chemotherapy","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","score":1.0,"display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G1281411269","display_name":null,"funder_award_id":"HHSO100201900007C","funder_id":"https://openalex.org/F4320333299","funder_display_name":"Biomedical Advanced Research and Development Authority"},{"id":"https://openalex.org/G183654798","display_name":null,"funder_award_id":"75A50122C00080","funder_id":"https://openalex.org/F4320333299","funder_display_name":"Biomedical Advanced Research and Development Authority"},{"id":"https://openalex.org/G818512182","display_name":null,"funder_award_id":"HHSO100201900007C","funder_id":"https://openalex.org/F4320306085","funder_display_name":"U.S. Department of Health and Human Services"}],"funders":[{"id":"https://openalex.org/F4320306085","display_name":"U.S. Department of Health and Human Services","ror":"https://ror.org/033jnv181"},{"id":"https://openalex.org/F4320307765","display_name":"Pfizer","ror":"https://ror.org/01xdqrp08"},{"id":"https://openalex.org/F4320307770","display_name":"AstraZeneca","ror":"https://ror.org/04r9x1a08"},{"id":"https://openalex.org/F4320310420","display_name":"CSL Behring","ror":"https://ror.org/01jxhxv92"},{"id":"https://openalex.org/F4320311052","display_name":"Deutsches Zentrum f\u00fcr Infektionsforschung","ror":"https://ror.org/028s4q594"},{"id":"https://openalex.org/F4320320879","display_name":"Deutsche Forschungsgemeinschaft","ror":"https://ror.org/018mejw64"},{"id":"https://openalex.org/F4320321703","display_name":"European Association of Urology","ror":"https://ror.org/00m9mc973"},{"id":"https://openalex.org/F4320323024","display_name":"Astellas Pharma","ror":"https://ror.org/01cjash87"},{"id":"https://openalex.org/F4320323316","display_name":"Shionogi","ror":"https://ror.org/01v3bqg10"},{"id":"https://openalex.org/F4320323906","display_name":"Vifor Pharma","ror":"https://ror.org/0185z7g17"},{"id":"https://openalex.org/F4320325874","display_name":"Uniklinikum Giessen und Marburg","ror":"https://ror.org/032nzv584"},{"id":"https://openalex.org/F4320333299","display_name":"Biomedical Advanced Research and Development Authority","ror":"https://ror.org/029y69023"}],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4398237253.pdf","grobid_xml":"https://content.openalex.org/works/W4398237253.grobid-xml"},"referenced_works_count":26,"referenced_works":["https://openalex.org/W2028883721","https://openalex.org/W2793280651","https://openalex.org/W2797166511","https://openalex.org/W2898144230","https://openalex.org/W2922512490","https://openalex.org/W2922975437","https://openalex.org/W2990621521","https://openalex.org/W2995120671","https://openalex.org/W3024858639","https://openalex.org/W4206256251","https://openalex.org/W4206571317","https://openalex.org/W4211149540","https://openalex.org/W4214922586","https://openalex.org/W4224092216","https://openalex.org/W4242318543","https://openalex.org/W4297613952","https://openalex.org/W4300981157","https://openalex.org/W4311737358","https://openalex.org/W4312064895","https://openalex.org/W4313293234","https://openalex.org/W4315435880","https://openalex.org/W4366351459","https://openalex.org/W4384665204","https://openalex.org/W4386304161","https://openalex.org/W4387115863","https://openalex.org/W4391824460"],"related_works":["https://openalex.org/W4389031451","https://openalex.org/W4311598383","https://openalex.org/W4399116976","https://openalex.org/W4389029586","https://openalex.org/W4396813922","https://openalex.org/W3214262295","https://openalex.org/W4399280518","https://openalex.org/W2757905609","https://openalex.org/W3120659528","https://openalex.org/W4402576008"],"abstract_inverted_index":{"ABSTRACT":[0],"CERTAIN-1":[1],"was":[2],"a":[3,169],"Phase":[4],"3,":[5],"double-blind,":[6],"randomized,":[7],"parallel":[8],"group":[9],"study":[10,232],"of":[11,16,23,37,69,108],"the":[12,21],"efficacy":[13,210],"and":[14,39,46,48,55,86,95,138,162,187,203,218,226],"safety":[15],"cefepime-taniborbactam":[17,45],"versus":[18],"meropenem":[19,127],"in":[20,60,110,126,155,183,190,211],"treatment":[22,100],"adults":[24],"with":[25,145,159,166,168,194,215,223,235],"complicated":[26],"urinary":[27],"tract":[28],"infection":[29],"(cUTI),":[30],"including":[31,221],"acute":[32],"pyelonephritis.":[33],"We":[34],"determined":[35],"susceptibility":[36],"Enterobacterales":[38,81,161,167],"Pseudomonas":[40],"aeruginosa":[41,196],"baseline":[42,65,82],"pathogens":[43,66,220,222],"to":[44,118],"comparators":[47],"characterized":[49],"\u03b2-lactam":[50],"resistance":[51],"mechanisms.":[52],"Microbiologic":[53],"response":[54,57],"clinical":[56,188],"were":[58,68,116,129,200],"assessed":[59],"patient":[61],"subsets":[62,112],"defined":[63],"by":[64,113,120],"that":[67,76],"cefepime-,":[70,216],"multidrug-,":[71,217],"or":[72,75],"carbapenem-resistant":[73,160,219],"phenotype":[74],"carried":[77,88],"\u03b2-lactamase":[78],"genes.":[79,228],"Among":[80],"pathogens,":[83],"26.8%,":[84],"4.1%,":[85],"3.0%":[87],"genes":[89],"for":[90,132,206],"extended-spectrum":[91],"\u03b2-lactamases":[92],"(ESBLs),":[93],"AmpC,":[94,225],"carbapenemases,":[96],"respectively.":[97],"Within":[98],"each":[99],"group,":[101],"while":[102],"composite":[103,123,153,181],"success":[104,124,154,182,189],"rates":[105,125,199],"at":[106],"Test":[107],"Cure":[109],"resistant":[111],"pathogen":[114,121],"species":[115],"similar":[117],"those":[119],"overall,":[122],"patients":[128,158,165,186,193,214],"numerically":[130],"lower":[131],"cefepime-resistant":[133],"Escherichia":[134],"coli":[135,141,147],"(9/19;":[136],"47.4%)":[137],"ESBL":[139],"E.":[140,146],"(13/25;":[142],"52.0%)":[143],"compared":[144],"overall":[148],"(62/100;":[149],"62.0%).":[150],"Cefepime-taniborbactam":[151,178,208],"achieved":[152,180],"7/8":[156],"(87.5%)":[157],"8/9":[163],"(88.9%)":[164],"carbapenemase":[170,227],"gene":[171],"(5":[172],"OXA-48-group;":[173],"2":[174,176],"KPC-3;":[175],"NDM-1).":[177],"also":[179],"8/16":[184],"(50.0%)":[185],"13/16":[191],"(81.3%)":[192],"P.":[195],";":[197],"corresponding":[198],"4/7":[201],"(57.1%)":[202],"6/7":[204],"(85.7%)":[205],"meropenem.":[207],"demonstrated":[209],"adult":[212],"cUTI":[213],"ESBL,":[224],"CLINICAL":[229],"TRIALS":[230],"This":[231],"is":[233],"registered":[234],"ClinicalTrials.gov":[236],"as":[237],"NCT03840148":[238],".":[239]},"counts_by_year":[{"year":2026,"cited_by_count":14},{"year":2025,"cited_by_count":14},{"year":2024,"cited_by_count":1}],"updated_date":"2026-11-13T13:42:25.865203","created_date":"2024-05-24T00:00:00"}